Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
benzinga.com
Thursday, Ionis Pharmaceuticals Inc IONS and Biogen Inc BIIB decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for…